TipRanks on MSN

Valneva reports positive phase 2 results for chikungunya vaccine in children

An announcement from Valneva ( ($VALN) ) is now available. Valneva SE announced positive final results from its Phase 2 clinical trial for the ...
Investing.com India

Valneva stock rises after positive final Phase 2 results for chikungunya vaccine

Investing.com -- Valneva SE (NASDAQ:VALN) stock gained 3.7% on Thursday after the specialty vaccine company reported positive final Phase 2 antibody persistence and safety results for its chikungunya ...

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups, ...
TipRanks on MSN

Valneva reports 'positive' final phase 2 results for chikungunya vaccine

Valneva (VALN) announced “positive” final antibody persistence and safety data for its Phase 2 clinical trial evaluating the ...
The Munich Eye

Rise in Imported Chikungunya Cases Linked to Cuba Outbreak

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.